CSL
- Short interest
- 1.11%
- −0.32 pp 30d
- as of 9 Oct 2026
- Reported shorts
- 5.3M
- Shares on issue
- 479.884M
CSL (CSL) Short Interest
CSL (ASX:CSL) had 1.11% of shares reported as short positions as of 9 Oct 2026, representing 5,333,614 shares. CSL operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About CSL
CSL Limited is a global biotechnology company specializing in the development, manufacturing, and marketing of life-saving biotherapies, vaccines, and diagnostic products. Its core business revolves around plasma-derived therapies, which treat a range of serious medical conditions, and recombinant technologies. CSL holds a leading market position in several therapeutic areas, leveraging its extensive research and development capabilities and global manufacturing and distribution network to deliver innovative healthcare solutions.
Company profile →CSL (ASX:CSL) has 1.11% of its shares on issue reported as short positions as of 9 Oct 2026, or about 5,333,614 shares. Over the past 30 days that figure has fallen 0.32 percentage points, and over 90 days it has been broadly flat. Its highest recorded short interest was 3.33% in June 2010. CSL is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads CSL today
- Zanger BreakoutWatchScore 20rank 1207 of 1942
- CAN SLIMWatchScore 25rank 417 of 1541
- Minervini Trend TemplateWatchScore 58rank 209 of 1716
- Crowded-Short BreakoutWatchScore 25rank 176 of 1500
- Quality compoundersWatchScore 43rank 207 of 1669
Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
CSL fundamentals
In the year to 30 Jun 2026, CSL (ASX:CSL) recorded revenue of US$15.7B and a net loss after tax of US$2.6B. A year earlier it recorded revenue of US$15.4B and net profit after tax of US$3.0B. Year-on-year growth: revenue +1.7% (FY). Net margin −16.4%, return on equity −15.1% (FY). Figures are in USD, the company's reporting currency; source: Yahoo Finance, as at 14 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest CSL news
All news- Lixudebart Deal Could Be A Game Changer For CSL (ASX:CSL) - Simply Wall Street
googlenews · 13 Oct 2026
- How Is ASX 200 Stock CSL (ASX:CSL) Rebuilding Plasma Growth After a Reset? - Kalkine Media
googlenews · 13 Oct 2026
- CSL, Westpac, BHP shares: Buy, hold, or sell?
motleyfool · 13 Oct 2026
Company details
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss CSL
Start a research thread or post the first pulse update